کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2473436 | 1113015 | 2011 | 12 صفحه PDF | دانلود رایگان |
We compare the design, mechanism of action, and clinical efficacy of two recently licensed paradigm shifting vaccines. Zostavax is the first vaccine licensed to prevent disease in patients already infected with a pathogen, and is contrasted with Gardasil and Cervarix, the first vaccines designed and licensed specifically to prevent cancers.
► HPV vaccines are effective at preventing HPV related anogenital disease in men and women previously uninfected with HPV.
► Evidence of field efficacy of HPV vaccines is now available.
► As with most vaccines, induced antibody is of limited efficacy as a surrogate marker for protection.
► The herpes zoster vaccine is the first to prevent the consequences of reactivation of a latent infection.
► This vaccine prevents herpes zoster and often attenuates the disease when prevention fails.
► These beneficial effects of vaccination decline significantly at age 80 and greater.
Journal: Current Opinion in Virology - Volume 1, Issue 4, October 2011, Pages 268–279